Intravenous @entity2778 for the treatment of XXXX and @entity5069 after cardiopulmonary bypass. Comparison with @entity7306 and digoxin in a randomised trial.

@entity1 @entity2778 @entity7306 @entity955 @entity2922 @entity943 @entity1168 @entity5069
The efficacy of @entity2778 in treating acute @entity955 and @entity5069 after open heart surgery was compared with that of a digoxin/ @entity7306 combination. Forty adult @entity1 with postoperative @entity943 were randomised into either group 1 ( @entity2778 1 mg/kg bolus intravenously plus 0.2 mg/kg intravenously over 12 hours) or group 2 (digoxin 0.75 mg intravenously, then two hours later @entity7306 2 mg/kg intravenous bolus and 0.4 mg/kg/h intravenously for 10 hours). In each group, 17 out of 20 @entity1 reverted to sinus or junctional rhythm within 12 hours. The time to reversion in group 1 was significantly shorter than in group 2. Systolic blood pressure fell by greater than or equal to 20 mm Hg or to less than or equal to 90 mm Hg during drug administration in 17 out of 20 @entity1 in group 1 ( @entity2778 withdrawn in two) and in none out of 20 in group 2. Two @entity1 in group 1 developed transient @entity1168 ( @entity2778 withdrawn in one). None of 17 @entity1 in group 1 and two of 17 in group 2 relapsed temporarily into @entity955 during the 12 hours of intravenous treatment. On continued oral treatment, one late relapse occurred in group 1 and five in group 2, and five @entity1 in group 2 had @entity7306 withdrawn because of anticholinergic side effects (acute urinary retention in four). @entity2778 was as effective as the digoxin/ @entity7306 combination and acted significantly faster. Sensitivity to beta blockade in these @entity1 may be related to high plasma @entity2922 concentrations known to occur after cardiopulmonary bypass.
